A systematic review of community based hepatitis C treatment

被引:42
作者
Wade, Amanda J. [1 ,2 ]
Veronese, Vanessa [1 ,2 ]
Hellard, Margaret E. [1 ,2 ,3 ]
Doyle, Joseph S. [1 ,3 ,4 ]
机构
[1] Burnet Inst, Ctr Populat Hlth, Melbourne, Vic, Australia
[2] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic 3004, Australia
[3] Alfred Hosp, Dept Infect Dis, Melbourne, Vic, Australia
[4] Univ Melbourne, Dept Med, Melbourne, Vic, Australia
来源
BMC INFECTIOUS DISEASES | 2016年 / 16卷
关键词
Hepatitis C; Community-based; Opioid substitution; Treatment; Models of care; INJECTION-DRUG USERS; VIRUS-INFECTION; RIBAVIRIN; OUTCOMES; PEOPLE; RECOMMENDATIONS; MANAGEMENT; THERAPY; CANADA;
D O I
10.1186/s12879-016-1548-5
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Hepatitis C virus (HCV) treatment uptake globally is low. A barrier to treatment is the necessity to attend specialists, usually in a tertiary hospital. We investigate the literature to assess the effect of providing HCV treatment in the community on treatment uptake and cure. Methods: Three databases were searched for studies that contained a comparison between HCV treatment uptake or sustained virologic response (SVR) in a community site and a tertiary site. Treatment was with standard interferon with or without ribavirin, or pegylated interferon and ribavirin. A narrative synthesis was conducted. Results: Thirteen studies fulfilled the inclusion criteria. Six studies measured treatment uptake; three demonstrated an increase in uptake at the community site, two demonstrated similar rates between sites and one demonstrated decreased uptake at the community site. Nine studies measured SVR; four demonstrated higher SVR rates in the community, four demonstrated similar SVR rates, and one demonstrated inferior SVR rates in the community compared to the tertiary site. Conclusion: The data available supports the efficacy of HCV treatment in the community, and the potential for community based treatment to increase treatment uptake. Whilst further studies are required, these findings highlight the potential benefit of providing community based HCV care - benefits that should be realised as interferon-free therapy become available.
引用
收藏
页数:8
相关论文
共 27 条
  • [11] Comparison Stratagems of Post-Screening Management of Anti-HCV-Positive Community Residents: Simple Notification, Active Referral, or Accessible Medical Care
    Kuo, Yuan-Hung
    Chen, Pao-Fei
    Wang, Jing-Houng
    Chang, Kuo-Chin
    Kee, Kwong-Ming
    Tsai, Ming-Chao
    Lin, Chun-Yin
    Lin, Sheng-Che
    Tsai, Lin-San
    Chen, Shu-Chuan
    Lu, Sheng-Nan
    [J]. PLOS ONE, 2015, 10 (05):
  • [12] Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program
    Litwin, Alain H.
    Harris, Kenneth A., Jr.
    Nahvi, Shadi
    Zamor, Philippe J.
    Soloway, Irene J.
    Tenore, Peter L.
    Kaswan, Daniel
    Gourevitch, Marc N.
    Arnsten, Julia H.
    [J]. JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2009, 37 (01) : 32 - 40
  • [13] Hepatitis C Virus Treatment for Prevention Among People Who Inject Drugs: Modeling Treatment Scale-Up in the Age of Direct-Acting Antivirals
    Martin, Natasha K.
    Vickerman, Peter
    Grebely, Jason
    Hellard, Margaret
    Hutchinson, Sharon J.
    Lima, Viviane D.
    Foster, Graham R.
    Dillon, John F.
    Goldberg, David J.
    Dore, Gregory J.
    Hickman, Matthew
    [J]. HEPATOLOGY, 2013, 58 (05) : 1598 - 1609
  • [14] Moriarty H, 2001, NEW ZEAL MED J, V114, P105
  • [15] Factors to Improve the Management of Hepatitis C in Drug Users: An Observational Study in an Addiction Centre
    Moussalli, Joseph
    Delaquaize, Helene
    Boubilley, Dominique
    Lhomme, Jean Pierre
    Ponty, Jules Merleau
    Sabot, David
    Kerever, Anne
    Valleur, Marc
    Poynard, Thierry
    [J]. GASTROENTEROLOGY RESEARCH AND PRACTICE, 2010, 2010
  • [16] Outcomes of chronic hepatitis C therapy in patients treated in community versus academic centres in Canada: Final results of APPROACH (A Prospective study of Peginterferon alfa-2a and Ribavirin at Academic and Community Centres in Canada)
    Myers, Robert P.
    Cooper, Curtis
    Sherman, Morris
    Lalonde, Richard
    Witt-Sullivan, Helga
    Elkashab, Magdy
    Harris, Paul
    Balshaw, Rob
    Usaty, Christopher
    Marotta, Paul J.
    [J]. CANADIAN JOURNAL OF GASTROENTEROLOGY, 2011, 25 (09): : 503 - 510
  • [17] Physicians' attitudes and practice toward treating injection drug users infected with hepatitis C virus: Results from a national specialist survey in Canada
    Myles, Angelique
    Mugford, Gerry J.
    Zhao, Jing
    Krahn, Murray
    Wang, Peizhong Peter
    [J]. CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2011, 25 (03): : 135 - 139
  • [18] Successful treatment of patients with hepatitis C in rural and remote Western Australia via telehealth
    Nazareth, Saroja
    Kontorinis, Nickolas
    Muwanwella, Niroshan
    Hamilton, Alan
    Leembruggen, Nadine
    Cheng, Wendy S. C.
    [J]. JOURNAL OF TELEMEDICINE AND TELECARE, 2013, 19 (02) : 101 - 106
  • [19] Treatment of chronic hepatitis C infection among current and former injection drug users within a multidisciplinary treatment model at a community health centre
    Newman, Adam I.
    Beckstead, Shelley
    Beking, David
    Finch, Susan
    Knorr, Tina
    Lynch, Carol
    MacKenzie, Meredith
    Mayer, Daphne
    Melles, Brenda
    Shore, Ron
    [J]. CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 27 (04) : 217 - 223
  • [20] Noncompliance with guidelines for the treatment of hepatitis C is frequent in daily practice
    Niederau, Claus
    Mauss, Stefan
    Boeker, Klaus
    Lutz, Thomas
    Heyne, Renate
    Moog, Gero
    John, Christine
    Witthoeft, Thomas
    Alshuth, Ulrich
    Hueppe, Dietrich
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2014, 26 (01) : 65 - 73